<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="http://medicalxpress.com/tmpl/default/css/default/feedRSS.xsl"?>
<rss version="2.0" 
	xmlns:media="http://search.yahoo.com/mrss/">
<channel>
<title>Medical Xpress: PHYSorg news tagged with: resistant cells</title>
<link>http://medicalxpress.com/</link>
<language>en-us</language> 
<description>Medical Xpress internet news portal provides the latest news on Health and Medicine.</description>

 <item>
     <title>New therapy holds promise for aggressive breast cancers</title>
   	 <description>Australian researchers have developed a new therapy to treat a common and aggressive form of breast cancer and stop the disease spreading, with a 100% success rate reported in mice.</description>
     <link>http://medicalxpress.com/news/2013-04-therapy-aggressive-breast-cancers.html</link>
	 <category>Cancer</category>
	 <pubDate>Tue, 16 Apr 2013 09:05:41 EST</pubDate>
	 <guid isPermaLink="false">news285321933</guid>
	 <media:thumbnail url="http://s.ph-cdn.com/newman/gfx/news/tmb/2013/newtherapyho.jpg" width="90" height="90" />
</item>
<item>
     <title>Virus shows promise as prostate cancer treatment</title>
   	 <description>A recombinant Newcastle disease virus kills all kinds of prostate cancer cells, including hormone resistant cells, but leaves normal cells unscathed, according to a paper published online ahead of print in the Journal of Virology. A treatment for prostate cancer based on this virus would avoid the adverse side effects typically associated with hormonal treatment for prostate cancer, as well as those associated with cancer chemotherapies generally, says corresponding author Subbiah Elankumaran of Virginia Polytechnic Institute, Blacksburg. The modified virus is now ready to be tested in preclinical animal models, and possibly in phase I human clinical trials.</description>
     <link>http://medicalxpress.com/news/2013-02-virus-prostate-cancer-treatment.html</link>
	 <category>Cancer</category>
	 <pubDate>Mon, 25 Feb 2013 16:07:17 EST</pubDate>
	 <guid isPermaLink="false">news281030816</guid>
	 
</item>
<item>
     <title>Antibody hinders growth of Gleevec-resistant gastrointestinal tumors in lab tests</title>
   	 <description>An antibody that binds to a molecule on the surface of a rare but deadly tumor of the gastrointestinal tract inhibits the growth of the cancer cells in mice, according to researchers at the Stanford University School of Medicine.</description>
     <link>http://medicalxpress.com/news/2013-02-antibody-hinders-growth-gleevec-resistant-gastrointestinal.html</link>
	 <category>Cancer</category>
	 <pubDate>Mon, 04 Feb 2013 15:00:08 EST</pubDate>
	 <guid isPermaLink="false">news279195778</guid>
	 
</item>
<item>
     <title>Treatment targeting PI3K may delay resistance to anti-HER2 therapy in breast cancer patients</title>
   	 <description>Patients with HER2-positive breast cancer being treated with anti-HER2 therapy may be able to prevent or delay resistance to the therapy with the addition of a phosphatidylinositol-3 kinase inhibitor to their treatment regimens.</description>
     <link>http://medicalxpress.com/news/2013-01-treatment-pi3k-resistance-anti-her2-therapy.html</link>
	 <category>Cancer</category>
	 <pubDate>Wed, 23 Jan 2013 13:59:45 EST</pubDate>
	 <guid isPermaLink="false">news278171977</guid>
	 
</item>
<item>
     <title>Hedgehog pathway key in tamoxifen-resistant breast CA</title>
   	 <description>(HealthDay)—Noncanonical Hedgehog (Hh) signaling is activated in tamoxifen-resistant tumors, and the phosphoinositide 3-kinase inhibitor/protein kinase B (PI3K/AKT) pathway plays a key role protecting Hh signaling molecules, according to a study published in the Oct. 1 issue of Cancer Research.</description>
     <link>http://medicalxpress.com/news/2012-11-hedgehog-pathway-key-tamoxifen-resistant-breast.html</link>
	 <category>Cancer</category>
	 <pubDate>Tue, 06 Nov 2012 16:40:01 EST</pubDate>
	 <guid isPermaLink="false">news271441074</guid>
	 <media:thumbnail url="http://s.ph-cdn.com/newman/gfx/news/tmb/2012/hedgehogpath.jpg" width="90" height="90" />
</item>
<item>
     <title>How do cancers become resistant to chemotherapy?</title>
   	 <description>Genetic mutations in cancer cells can lead to resistance to treatment, thereby potentially resulting in relapse. However, a new article, published April 3 in the magazine section of the online, open-access journal PLoS Biology, suggests that the converse may also happen. Steven Frank from the University of California, Irvine, and Marsha Rosner from the University of Chicago, propose that it may often be the case that a few cells become resistant before any genetic change, and then later acquire the genes to stabilize that resistance.</description>
     <link>http://medicalxpress.com/news/2012-04-cancers-resistant-chemotherapy.html</link>
	 <category>Cancer</category>
	 <pubDate>Tue, 03 Apr 2012 17:00:01 EST</pubDate>
	 <guid isPermaLink="false">news252689283</guid>
	 
</item>
<item>
     <title>Mushroom compound appears to improve effectiveness of cancer drugs</title>
   	 <description>A compound isolated from a wild, poisonous mushroom growing in a Southwest China forest appears to help a cancer killing drug fulfill its promise, researchers report.</description>
     <link>http://medicalxpress.com/news/2011-10-mushroom-compound-effectiveness-cancer-drugs.html</link>
	 <category>Cancer</category>
	 <pubDate>Tue, 11 Oct 2011 12:57:54 EST</pubDate>
	 <guid isPermaLink="false">news237556666</guid>
	 <media:thumbnail url="http://s.ph-cdn.com/newman/gfx/news/tmb/2011/1-mushroomcomp.jpg" width="90" height="84" />
</item>


</channel>
</rss>
